⁃ A. Confirmed diagnosis of a ROS1 gene fusion-positive malignancy, other than NSCLC, that has been identified using an analytically validated next-generation sequencing method.

⁃ B. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and/or trephine or lymph node biopsy samples may be taken.

⁃ C. Patients with a BSA of 0.43m\^2 and over.

⁃ D. ADULT PATIENTS (≥18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.

⁃ E. PAEDIATRIC PATIENTS (\<18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.

⁃ F. Women of childbearing potential are eligible provided that they meet the following criteria:

• Have a negative serum or urine pregnancy test before enrolment and either:

• Agree to use one form of highly effective birth control method such as:

⁃ I. Oral, intravaginal or transdermal combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation

⁃ II. Oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation

⁃ III. Intrauterine device (IUD)

⁃ IV. Intrauterine hormone-releasing system (IUS)

⁃ V. Bilateral tubal occlusion

⁃ VI. Vasectomised partner

⁃ Plus a barrier method if using a hormonal method: male or female condom with or without spermicide; cap, diaphragm or sponge with spermicide OR

⁃ • Sexual abstinence;

⁃ Effective from the first administration of entrectinib, throughout the trial and for five weeks after the last administration of entrectinib.

⁃ G. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of entrectinib, throughout the trial and for three months after the last administration of entrectinib:

• Agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence.

• Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses a highly effective method of contraception as in F above.

• Male patients with pregnant or lactating partners must be advised to use barrier method contraception (e.g. condom) to prevent drug exposure of the foetus or neonate.

⁃ All male patients must refrain from donating sperm for the same period.